Effects of peroxisome proliferator-activated receptor γ in simvastatin antiplatelet activity: Influences on cAMP and mitogen-activated protein kinases

Thrombosis Research

Volumn 134, Issue 1, 2014, Pages 111-120

  Du, Hong ^a   Hu, Haijuan ^a   Zheng, Hongmei ^a   Hao, Jie ^a   Yang, Jingci ^a   Cui, Wei ^a  

^a HEBEI MEDICAL UNIVERSITY   (China)

Author keywords

Cyclic adenosine monophosphate; Mitogen activated protein kinase; Peroxisome proliferator activated receptor; Platelet activation; Simvastatin; Statin

Indexed keywords

CYCLIC AMP; HYPOCHOLESTEROLEMIC AGENT; MITOGEN ACTIVATED PROTEIN KINASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; SIMVASTATIN;

CORONARY ARTERY DISEASE; DRUG EFFECTS; HUMAN; METABOLISM; THROMBOCYTE; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION;

ANTICHOLESTEREMIC AGENTS; BLOOD PLATELETS; CORONARY ARTERY DISEASE; CYCLIC AMP; HUMANS; MITOGEN-ACTIVATED PROTEIN KINASES; PLATELET ACTIVATION; PLATELET AGGREGATION; PPAR GAMMA; SIMVASTATIN;

EID: 84902551536     PISSN: 00493848     EISSN: 18792472     Source Type: Journal    
DOI: 10.1016/j.thromres.2014.05.005     Document Type: Article

References (53)

1. I.A. Relou, C.M. Hackeng, J.W. Akkerman, and E. Malle Low-density lipoprotein and its effect on human blood platelets Cell Mol Life Sci 60 5 2003 961 971
2. G. Davi, M. Averna, I. Catalano, C. Barbagallo, A. Ganci, and A. Notarbartolo et al. Increased thromboxane biosynthesis in type IIa hypercholesterolemia Circulation 85 5 1992 1792 1798
3. M. Labios, M. Martinez, F. Gabriel, V. Guiral, E. Martinez, and J. Aznar Effect of atorvastatin upon platelet activation in hypercholesterolemia, evaluated by flow cytometry Thromb Res 115 4 2005 263 270
4. A. Notarbartolo, G. Davi, M. Averna, C. Barbagallo, A. Ganci, and C. Giammarresi et al. Inhibition of thromboxane biosynthesis and platelet function by simvastatin in type IIa hypercholesterolemia Arterioscler Thromb Vasc Biol 15 2 1995 247 251
5. D.K. Vora, Z.T. Fang, S.M. Liva, T.R. Tyner, F. Parhami, and A.D. Watson et al. Induction of P-selectin by oxidized lipoproteins. Separate effects on synthesis and surface expression Circ Res 80 6 1997 810 818
6. 2 + and membrane dynamics in patients with primary hypercholesterolemia. Effects of pravastatin Arterioscler Thromb Vasc Biol 15 6 1995 759 764
7. T. Lenderink, E. Boersma, A.K. Gitt, U. Zeymer, L. Wallentin, and F. Van de Werf et al. Patients using statin treatment within 24 h after admission for ST-elevation acute coronary syndromes had lower mortality than non-users: a report from the first Euro Heart Survey on acute coronary syndromes Eur Heart J 27 15 2006 1799 1804
8. J.R. Schaefer Lipid management for the prevention of cardiovascular disease Curr Pharm Des 17 9 2011 852 860
9. R.H. Knopp Drug treatment of lipid disorders N Engl J Med 341 7 1999 498 511
10. T. Tekten, C. Ceyhan, E. Ercan, A.O. Onbasili, and C. Turkoglu The effect of atorvastatin on platelet function in patients with coronary artery disease Acta Cardiol 59 3 2004 311 315
11. L. Puccetti, F. Santilli, A.L. Pasqui, S. Lattanzio, R. Liani, and F. Ciani et al. Effects of atorvastatin and rosuvastatin on thromboxane-dependent platelet activation and oxidative stress in hypercholesterolemia Atherosclerosis 214 1 2011 122 128
12. L.P. Ma, D.N. Nie, S.X. Hsu, S.M. Yin, L.Z. Xu, and J.V. Nunes Inhibition of platelet aggregation and expression of alpha granule membrane protein 140 and thromboxane B2 with pravastatin therapy for hypercholesterolemia J Assoc Acad Minor Phys 13 1 2002 23 26
13. F.Y. Ali, P.C. Armstrong, A.R. Dhanji, A.T. Tucker, M.J. Paul-Clark, and J.A. Mitchell et al. Antiplatelet actions of statins and fibrates are mediated by PPARs Arterioscler Thromb Vasc Biol 29 5 2009 706 711
14. C.H. Lee, A. Chawla, N. Urbiztondo, D. Liao, W.A. Boisvert, and R.M. Evans et al. Transcriptional repression of atherogenic inflammation: modulation by PPARdelta Science 80 2003 302(5644): 453-7
15. H. Inoue, X.F. Jiang, T. Katayama, S. Osada, K. Umesono, and S. Namura Brain protection by resveratrol and fenofibrate against stroke requires peroxisome proliferator-activated receptor alpha in mice Neurosci Lett 352 3 2003 203 206
16. F.Y. Ali, S.J. Davidson, L.A. Moraes, S.L. Traves, M. Paul-Clark, and D. Bishop-Bailey et al. Role of nuclear receptor signaling in platelets: antithrombotic effects of PPARbeta FASEB J 20 2 2006 326 328
17. J.R. Sheu, C.R. Lee, C.H. Lin, G. Hsiao, W.C. Ko, and Y.C. Chen et al. Mechanisms involved in the antiplatelet activity of Staphylococcus aureus lipoteichoic acid in human platelets Thromb Haemost 83 5 2000 777 784
18. Y.M. Lee, W.F. Chen, D.S. Chou, T. Jayakumar, S.Y. Hou, and J.J. Lee et al. Cyclic nucleotides and mitogen-activated protein kinases: regulation of simvastatin in platelet activation J Biomed Sci 17 2010 45
19. H.E. Xu, T.B. Stanley, and V.G. Montana et al. Structural basis for antagonist-mediated recruitment of nuclear co-repressors by PPARalpha Nature 415 6873 2002 813 817
20. L.M. Leesnitzer, D.J. Parks, and R.K. Bledsoe et al. Functional consequences of cysteine modification in the ligand binding sites of peroxisome proliferator activated receptors by GW9662 Biochemistry 41 21 2002 6640 6650
21. S.M. Kamruzzaman, T. Yayeh, H.D. Ji, J.Y. Park, Y.S. Kwon, and I.K. Lee et al. p-Terphenyl curtisian E inhibits in vitro platelet aggregation via cAMP elevation and VASP phosphorylation Vasc Pharmacol 59 3-4 2013 83 89
22. C.Y. Shih, and T.C. Chou The antiplatelet activity of magnolol is mediated by PPAR-beta/gamma Biochem Pharmacol 84 6 2012 793 803
23. A. Aszodi, A. Pfeifer, M. Ahmad, M. Glauner, X.H. Zhou, and L. Ny et al. The vasodilator-stimulated phosphoprotein (VASP) is involved in cGMP- and cAMP-mediated inhibition of agonist-induced platelet aggregation, but is dispensable for smooth muscle function EMBO J 18 1 1999 37 48
24. S.S. Smyth, D.S. Woulfe, J.I. Weitz, C. Gachet, P.B. Conley, and S.G. Goodman et al. G-protein-coupled receptors as signaling targets for antiplatelet therapy Arterioscler Thromb Vasc Biol 29 4 2009 449 457
25. J. Chen, S. De, D.S. Damron, W.S. Chen, N. Hay, and T.V. Byzova Impaired platelet responses to thrombin and collagen in AKT-1-deficient mice Blood 104 6 2004 1703 1710
26. P. Flevaris, Z. Li, G. Zhang, Y. Zheng, J. Liu, and X. Du Two distinct roles of mitogen-activated protein kinases in platelets and a novel Rac1-MAPK-dependent integrin outside-in retractile signaling pathway Blood 113 4 2009 893 901
27. M. Takemoto, and J.K. Liao Pleiotropic effects of 3-hydroxy-3- methylglutaryl coenzyme a reductase inhibitors Arterioscler Thromb Vasc Biol 21 11 2001 1712 1719
28. R.S. Rosenson, and C.C. Tangney Antiatherothrombotic properties of statins: implications for cardiovascular event reduction JAMA 279 20 1998 1643 1650
29. H. Osamah, R. Mira, S. Sorina, K. Shlomo, and A. Michael Reduced platelet aggregation after fluvastatin therapy is associated with altered platelet lipid composition and drug binding to the platelets Br J Clin Pharmacol 44 1 1997 77 83
30. A.D. Michelson, and M.I. Furman Laboratory markers of platelet activation and their clinical significance Curr Opin Hematol 6 5 1999 342 348
31. S.J. Shattil, J.A. Hoxie, M. Cunningham, and L.F. Brass Changes in the platelet membrane glycoprotein IIb.IIIa complex during platelet activation J Biol Chem 260 20 1985 11107 11114
32. U.R. Schwarz, U. Walter, and M. Eigenthaler Taming platelets with cyclic nucleotides Biochem Pharmacol 62 9 2001 1153 1161
33. G. Wangorsch, E. Butt, R. Mark, K. Hubertus, J. Geiger, and T. Dandekar et al. Time-resolved in silico modeling of fine-tuned cAMP signaling in platelets: feedback loops, titrated phosphorylations and pharmacological modulation BMC Syst Biol 5 2011 178
34. F.Y. Ali, M.G. Hall, B. Desvergne, T.D. Warner, and J.A. Mitchell PPARbeta/delta agonists modulate platelet function via a mechanism involving PPAR receptors and specific association/repression of PKCalpha-brief report Arterioscler Thromb Vasc Biol 29 11 2009 1871 1873
35. S.P.R. Heemskerk JW, F.R.W. Bevers EM, and T. Lindhout Receptors and signalling mechanisms in the procoagulant response of platelets Platelets 11 2000 301 306
36. J. Chen, S. De, D.S. Damron, W.S. Chen, N. Hay, and T.V. Byzova Impaired platelet responses to thrombin and collagen in AKT-1-deficient mice Blood 104 6 2004 1703 1710
37. J.M. Gibbins Platelet adhesion signalling and the regulation of thrombus formation J Cell Sci 117 2004 3415 3425
38. H. Hayashi, and TS Effects of the cAMP-elevating agents cilostamide, cilostazol and forskolin on the phosphorylation of Akt and GSK-3β in platelets Thromb Haemost 102 2009 327 335
39. T. Kitamura, Y. Kitamura, S. Kuroda, Y. Hino, M. Ando, and K. Kotani et al. Insulin-induced phosphorylation and activation of cyclic nucleotide phosphodiesterase 3B by the serine-threonine kinase Akt Mol Cell Biol 19 9 1999 6286 6296
40. W. Zhang, and R.W. Colman Thrombin regulates intracellular cyclic AMP concentration in human platelets through phosphorylation/activation of phosphodiesterase 3A Blood 110 5 2007 1475 1482
41. F. Adam, A. Kauskot, J.P. Rosa, and M. Bryckaert Mitogen-activated protein kinases in hemostasis and thrombosis J Thromb Haemost 6 12 2008 2007 2016
42. E.C. Jackson, and A. McNicol Cyclic nucleotides inhibit MAP kinase activity in low-dose collagen-stimulated platelets Thromb Res 125 2 2010 147 151
43. P.E. Hughes, M.W. Renshaw, M. Pfaff, J. Forsyth, V.M. Keivens, and M.A. Schwartz et al. Suppression of integrin activation: a novel function of a Ras/Raf-initiated MAP kinase pathway Cell 88 4 1997 521 530
44. P. Flevaris, Z. Li, G. Zhang, Y. Zheng, J. Liu, and X. Du Two distinct roles of mitogen-activated protein kinases in platelets and a novel Rac1-MAPK-dependent integrin outside-in retractile signaling pathway Blood 113 4 2009 893 901
45. S. Roger MP, A. Habib, MJ, and J. PR Costimulation of the Gi-coupled ADP receptor and the Gq-coupled TXA 2 receptor is required for ERK2 activation in collagen-induced platelet aggregation FEBS Lett 556 1-3 2004 227 235
46. F.A. Kauskot, and A. Mazharian Involvement of the mitogen-activated protein kinase c-Jun NH 2-terminal kinase 1 in thrombus formation J Biol Chem 282 44 2007 31990 31999
47. A. Kuliopulos, R. Mohanlal, and L. Covic Effect of selective inhibition of the p38 MAP kinase pathway on platelet aggregation Thromb Haemost 92 6 2004 1387 1393
48. E. Toth-Zsamboki, C. Oury, H. Cornelissen, R. De Vos, J. Vermylen, and M.F. Hoylaerts P2X1-mediated ERK2 activation amplifies the collagen-induced platelet secretion by enhancing myosin light chain kinase activation J Biol Chem 278 47 2003 46661 46667
49. L. Coulon, C. Calzada, P. Moulin, E. Vericel, and M. Lagarde Activation of p38 mitogen-activated protein kinase/cytosolic phospholipase A2 cascade in hydroperoxide-stressed platelets Free Radic Biol Med 35 6 2003 616 625
50. T.C. Chou, C.Y. Shih, and Y.T. Chen Inhibitory effect of alpha-lipoic acid on platelet aggregation is mediated by PPARs J Agric Food Chem 59 7 2011 3050 3059
51. J.A. Lemos, M.A. Blazing, and S.D. Wiviott et al. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial JAMA 292 11 2004 1307 1316
52. D.H. Walter, S. Fichtlscherer, M.B. Britten, W. Auch-Schwelk, V. Schachinger, and A.M. Zeiher Benefits of immediate initiation of statin therapy following successful coronary stent implantation in patients with stable and unstable angina pectoris and Q-wave acute myocardial infarction Am J Cardiol 89 1 2002 1 6
53. J.S. Sidhu, D. Cowan, J.A. Tooze, and J.C. Kaski Peroxisome proliferator-activated receptor-gamma agonist rosiglitazone reduces circulating platelet activity in patients without diabetes mellitus who have coronary artery disease Am Heart J 147 6 2004 e25